FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386424337> ?p ?o ?g. }

• W4386424337 abstract "Abstract Background Type 2 diabetes (T2D) is an independent risk factor for Alzheimer's disease (AD). Exendin-4 (Ex-4), a widely used glucagon-like peptide-1 receptor agonist drug in the treatment of T2D, has been demonstrated the therapeutic effects on diabetic encephalopathy (DE). Especially, the Ex-4 ameliorates the tau hyperphosphorylation and cognitive impairment in DE. And these crucial alterations are also important bridge between T2D and AD. However, its unique mechanism is unclear. Methods The db/db mice, high-fat-diet (HFD) / streptozotocin (STZ)—induced diabetic (HF-diabetic) mice, and high-glucose-damaged (HGD) HT-22 hippocampal cells were enrolled to examine the effects of Ex-4 on AD-like changes in T2D. The Novel object recognition test (NORT) and Morris water maze test (MWMT) were conducted to evaluate the cognitive impairment. The Dickkopf-1 (DKK1) was employed to weaken the activation of the Wnt/β-catenin pathway to explore the mechanism of Ex-4 in protecting the brain functions. The JASPAR was based to predict the interaction between NeuroD1 and the promoter region of Ins2 . Moreover, the chromatin immunoprecipitation coupled with quantitative polymerase chain reaction (ChIP-qPCR) and luciferase reporter assays were performed. Results Ex-4 alleviated the tau hyperphosphorylation, increased the brain-derived insulin, and improved the PI3K/AKT/GSK3-β signalling in db/db mice, HF-diabetic mice, and HGD HT-22 hippocampal neuronal cells. The NORT and MWMT indicated that Ex-4 alleviated the learning and memory deficits in HF-diabetic mice. The inhibitor Dickkopf-1 (DKK1) of the Wnt/β-catenin pathway significantly blocked the protective effects of Ex-4. Regarding further molecular mechanisms, NeuroD1 was affected by Ex-4 in vivo and in vitro, and the knockdown or overexpression of NeuroD1 suggested its crucial role in promoting the brain insulin by Ex-4. Meanwhile, the ChIP‒qPCR and luciferase reporter assays confirmed the combination between NeuroD1 and the promoter region of the insulin-encoding gene Ins2 . And this interaction could be promoted by Ex-4. Conclusions Our study proposes that Ex-4 alleviates tau hyperphosphorylation and cognitive dysfunction by increasing Ins2 -derived brain insulin through the Wnt/β-catenin/NeuroD1 signaling in T2D. And its also show new lights on part of the progress and mechanism on treatment targets for the DE in T2D." @default.
• W4386424337 created "2023-09-05" @default.
• W4386424337 creator A5022321423 @default.
• W4386424337 creator A5022625306 @default.
• W4386424337 creator A5042003885 @default.
• W4386424337 creator A5044757881 @default.
• W4386424337 creator A5048785121 @default.
• W4386424337 creator A5049274501 @default.
• W4386424337 creator A5054988969 @default.
• W4386424337 creator A5057471586 @default.
• W4386424337 creator A5071962811 @default.
• W4386424337 creator A5081469118 @default.
• W4386424337 creator A5084756378 @default.
• W4386424337 date "2023-09-04" @default.
• W4386424337 modified "2023-10-14" @default.
• W4386424337 title "Exendin-4 ameliorates tau hyperphosphorylation and cognitive impairment in type 2 diabetes through acting on Wnt/β-catenin/NeuroD1 pathway" @default.
• W4386424337 cites W1629726001 @default.
• W4386424337 cites W1890019163 @default.
• W4386424337 cites W1955207589 @default.
• W4386424337 cites W1967949545 @default.
• W4386424337 cites W1970779072 @default.
• W4386424337 cites W1975487612 @default.
• W4386424337 cites W1978879182 @default.
• W4386424337 cites W1983997832 @default.
• W4386424337 cites W1985643944 @default.
• W4386424337 cites W1993303027 @default.
• W4386424337 cites W2011634611 @default.
• W4386424337 cites W2019262185 @default.
• W4386424337 cites W2022614808 @default.
• W4386424337 cites W2027317254 @default.
• W4386424337 cites W2045364370 @default.
• W4386424337 cites W2048294165 @default.
• W4386424337 cites W2050463440 @default.
• W4386424337 cites W2057410639 @default.
• W4386424337 cites W2061322766 @default.
• W4386424337 cites W2066536370 @default.
• W4386424337 cites W2094880658 @default.
• W4386424337 cites W2102743706 @default.
• W4386424337 cites W2106036385 @default.
• W4386424337 cites W2106879908 @default.
• W4386424337 cites W2128660756 @default.
• W4386424337 cites W2152355721 @default.
• W4386424337 cites W2157534230 @default.
• W4386424337 cites W2231558274 @default.
• W4386424337 cites W2295883823 @default.
• W4386424337 cites W2329648451 @default.
• W4386424337 cites W2539721213 @default.
• W4386424337 cites W2567736710 @default.
• W4386424337 cites W2606211344 @default.
• W4386424337 cites W2786962139 @default.
• W4386424337 cites W2891651161 @default.
• W4386424337 cites W3009441391 @default.
• W4386424337 cites W3016210007 @default.
• W4386424337 cites W3023071439 @default.
• W4386424337 cites W3045997188 @default.
• W4386424337 cites W3158533374 @default.
• W4386424337 cites W3194102878 @default.
• W4386424337 cites W3194829575 @default.
• W4386424337 cites W3204822148 @default.
• W4386424337 cites W4281564421 @default.
• W4386424337 cites W4283788161 @default.
• W4386424337 doi "https://doi.org/10.1186/s10020-023-00718-2" @default.
• W4386424337 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37667187" @default.
• W4386424337 hasPublicationYear "2023" @default.
• W4386424337 type Work @default.
• W4386424337 citedByCount "0" @default.
• W4386424337 crossrefType "journal-article" @default.
• W4386424337 hasAuthorship W4386424337A5022321423 @default.
• W4386424337 hasAuthorship W4386424337A5022625306 @default.
• W4386424337 hasAuthorship W4386424337A5042003885 @default.
• W4386424337 hasAuthorship W4386424337A5044757881 @default.
• W4386424337 hasAuthorship W4386424337A5048785121 @default.
• W4386424337 hasAuthorship W4386424337A5049274501 @default.
• W4386424337 hasAuthorship W4386424337A5054988969 @default.
• W4386424337 hasAuthorship W4386424337A5057471586 @default.
• W4386424337 hasAuthorship W4386424337A5071962811 @default.
• W4386424337 hasAuthorship W4386424337A5081469118 @default.
• W4386424337 hasAuthorship W4386424337A5084756378 @default.
• W4386424337 hasBestOaLocation W43864243371 @default.
• W4386424337 hasConcept C126322002 @default.
• W4386424337 hasConcept C134018914 @default.
• W4386424337 hasConcept C137620995 @default.
• W4386424337 hasConcept C148762608 @default.
• W4386424337 hasConcept C184235292 @default.
• W4386424337 hasConcept C2778198054 @default.
• W4386424337 hasConcept C2779134260 @default.
• W4386424337 hasConcept C2779280383 @default.
• W4386424337 hasConcept C2779483572 @default.
• W4386424337 hasConcept C2984863031 @default.
• W4386424337 hasConcept C44752575 @default.
• W4386424337 hasConcept C555293320 @default.
• W4386424337 hasConcept C62478195 @default.
• W4386424337 hasConcept C71924100 @default.
• W4386424337 hasConcept C86803240 @default.
• W4386424337 hasConcept C95444343 @default.
• W4386424337 hasConceptScore W4386424337C126322002 @default.
• W4386424337 hasConceptScore W4386424337C134018914 @default.
• W4386424337 hasConceptScore W4386424337C137620995 @default.
• W4386424337 hasConceptScore W4386424337C148762608 @default.
• W4386424337 hasConceptScore W4386424337C184235292 @default.

• next